LL-K9-3   Click here for help

GtoPdb Ligand ID: 12107

Compound class: Synthetic organic
Comment: LL-K9-3 is a small-molecule that induces simultaneous degradation of CDK9 and cyclin T1 (CDK9-Cyclin T1 heterodimers) that was developed for anti-tumour potential in transcriptionally addicted cancers [1]. It uses hydrophobic tagging technology (HyT) to induce polyubiquitination of CDK9-cyclin T1 complexes, as a mechanism to promote proteasome-mediated degradation of both proteins. In particular LL-K9-3 was evaluated for its inhibitory effects on CDK9 and androgen receptor-mediated signalling pathways in prostate cancer. LL-K9-3 elicits more potent anti-proliferative and pro-apoptotic effects than its parental CDK9 inhibitor BMS-387032 (a.k.a. SNS032), or than the CDK9-only PROTAC THAL-SNS-032.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 16
Topological polar surface area 205.65
Molecular weight 683.28
XLogP 2.76
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H]1CC[C@H]([C@@H](C1)OCC(=O)NCCS(=O)(=O)N1CCC(CC1)C(=O)Nc1ncc(s1)SCc1ncc(o1)C(C)(C)C)C(C)C
Isomeric SMILES O=C(NCCS(=O)(=O)N1CCC(CC1)C(=O)Nc1ncc(s1)SCc1ncc(C(C)(C)C)o1)CO[C@H]1[C@H](C(C)C)CC[C@@H](C)C1
InChI InChI=1S/C31H49N5O6S3/c1-20(2)23-8-7-21(3)15-24(23)41-18-26(37)32-11-14-45(39,40)36-12-9-22(10-13-36)29(38)35-30-34-17-28(44-30)43-19-27-33-16-25(42-27)31(4,5)6/h16-17,20-24H,7-15,18-19H2,1-6H3,(H,32,37)(H,34,35,38)/t21-,23+,24-/m1/s1
InChI Key NPRIWHDFWDSJRZ-YFNKSVMNSA-N
Bioactivity Comments
The DC50 values of LL-K9-3 for CDK9 and cyclin T1 are 0.66 and 0.59 μM respectively [1]. The ligand entry for BMS-387032 (a.k.a. SNS032) provides affinity/potency data for the CDK9-directed component of LL-K9-3 across a number of CDKs.